TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Volume of distribution (V1/F and V2/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Half-lives of gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects decline rate
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of toxicity of radio-chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Refusal rates for treatment intensifications and reductions
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline daily UUI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of post-treatment UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Completion rates for the GRACE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C-reaction protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APACHE II scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity of organic dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Total days in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical control (BC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: affected arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B to apolipoprotein A1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-density lipoprotein-2 cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in liver enzymes (ALT, AST, gamma-GT, TBIL, DBIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bone Mineral Density (BMD) percentage differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with anaesthetic method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgical conditions assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of local anaesthetic injected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic rituximab exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs of local PU care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healing of PUs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of type V MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: spheroequivalent refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epithelial thickness (ET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stromal thickness (ST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stromal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of H3N2v vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to discharge eligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically meaningful events of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor shrinkage > 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nodal downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distance between tumor and circumferential resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improvement in arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subsequent pregnancy success
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in PBAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intermenstrual bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: average recurrence to treatment time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants quitting NRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous abstinence rate from Week 9 to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lobene Index mean score for stain extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported after-hours EHR documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCP-reported spending more than 75% of the visit interacting with the patient
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Encounter documentation completion by the end of the next business day
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day readmissions for any cause
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day readmissions for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to sleep induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases able to sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Background rhythm speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean increase in whole body glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: competitive anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sCort daily levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sCort responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sAA responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically meaningful complications
Endpoint domain: Adverse events/effects
Primary endpoint: Visible residual defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induced bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resorption of the bone substitute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bladder disorder (OAB-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in postmicturition residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative mediastinal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of mediastinal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative blood product use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: edema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feeling of tightness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduction of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Success rate of asymptomatic patients or freely patent syringing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time between flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay of first flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental cost-effectiveness ratio for intracranial progression
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost-effectiveness ratio for overall progression
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ISCI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICPI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: orienting/regulatory capacity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percent reduction from baseline in focal seizure frequency/28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥50% responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vowel identification performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error rate in vowel identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of brain natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of atrial natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: survival of patients with heart failure
Endpoint domain: Mortality/survival
Primary endpoint: ALS risk
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of tracheal tube placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of tracheal tube placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of gastrin‐17, pepsinogen I and pepsinogen II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inflammation, activity, atrophy and number of lymphoid follicles in the antral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Height SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical ranges of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: hot flashes severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hot flashes daily frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Economy of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Handling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified global rating scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average grades of stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Omega-3 Index (O3I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abstinence from heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of continuous abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TT performance enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful remote ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median ablation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure times compared to control patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Physiologic disorganization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation Index (OI) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CVC-related bloodstream infections (CVC-BSI) with gram-negative rods
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of symptomatic thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological Complete Response (pathCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal sensitive responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: grade 2 or greater genitourinary morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: grade 2 or greater hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: grade 2 or greater gastrointestinal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total score on the BPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunization response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occupational role performance impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Days on sickness absence per month
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Use of psychotropic medication
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in PANSS Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean weight gain at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to discontinuation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of preterm birth less than 32 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of preterm birth less than 37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Presence of corneal superficial punctate keratitis 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Action Research Arm Test level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of current dose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: trough FEV1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dietary patterns reflecting core and non-core food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of obstacles contacted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance speed in obstacle-only trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary-task errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of deoxypyridinoline (DPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of placental infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intrauterine findings of abnormal blood velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postinduction middle ear pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irrigant penetration to WL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful treatment of trigger digits
Endpoint domain: Mortality/survival
Primary endpoint: Mean postoperative satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean postoperative range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Der p 1 allergen concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of septic pelvic thrombophlebitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: daily use of oral morphine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mobilization pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: labour market attachment
Endpoint domain: Life impact
Endpoint subdomain: Employment outcomes
Primary endpoint: Change in ELF (serum marker)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ishak fibrosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term smoking cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective appetite responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core-body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Larsen radiologic damage scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probing depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target lesion failure (TLF) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target vessel myocardial infarction (MI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late/very late definite stent thrombosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Interobserver agreement for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurable reduction of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concomitant narcotic medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: nausea medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rate of H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm density and motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Peak serum ethanol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency to stage 1 NREM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency to stage 2 NREM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median expiratory cyst volume percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: computed tomographic image-derived residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ratio of residual volume to total lung capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Headache Impact Test (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decline in acute medication intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reporting of 'anxiety'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GSH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phantom Limb Pain (PLP) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual limb pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious adverse events (SOS events)
Endpoint domain: Adverse events/effects
Primary endpoint: Pachymetry reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical Activity Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes